DE69733960T2 - Verwendung von Antikörpern gegen CD45RO Leukozytenantigen zur Immunmodulation - Google Patents

Verwendung von Antikörpern gegen CD45RO Leukozytenantigen zur Immunmodulation Download PDF

Info

Publication number
DE69733960T2
DE69733960T2 DE69733960T DE69733960T DE69733960T2 DE 69733960 T2 DE69733960 T2 DE 69733960T2 DE 69733960 T DE69733960 T DE 69733960T DE 69733960 T DE69733960 T DE 69733960T DE 69733960 T2 DE69733960 T2 DE 69733960T2
Authority
DE
Germany
Prior art keywords
antibody
cell
use according
cd45rb
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69733960T
Other languages
German (de)
English (en)
Other versions
DE69733960D1 (de
Inventor
I. Andrew LAZAROVITS
Sibrand Poppema
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alimmune Tucson Ariz Us LLC
Original Assignee
Research Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Technologies Inc filed Critical Research Corp Technologies Inc
Application granted granted Critical
Publication of DE69733960D1 publication Critical patent/DE69733960D1/de
Publication of DE69733960T2 publication Critical patent/DE69733960T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69733960T 1996-09-18 1997-09-17 Verwendung von Antikörpern gegen CD45RO Leukozytenantigen zur Immunmodulation Expired - Fee Related DE69733960T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/715,342 US6106834A (en) 1993-06-02 1996-09-18 Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
US715342 1996-09-18
PCT/US1997/016321 WO1998011918A1 (en) 1996-09-18 1997-09-17 Use of antibodies to cd45r leukocyte antigens for immunomodulation

Publications (2)

Publication Number Publication Date
DE69733960D1 DE69733960D1 (de) 2005-09-15
DE69733960T2 true DE69733960T2 (de) 2006-05-24

Family

ID=24873646

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733960T Expired - Fee Related DE69733960T2 (de) 1996-09-18 1997-09-17 Verwendung von Antikörpern gegen CD45RO Leukozytenantigen zur Immunmodulation

Country Status (8)

Country Link
US (3) US6106834A (enExample)
EP (1) EP0939652B1 (enExample)
JP (1) JP2001501607A (enExample)
AT (1) ATE301471T1 (enExample)
CA (1) CA2266684A1 (enExample)
DE (1) DE69733960T2 (enExample)
ES (1) ES2247638T3 (enExample)
WO (1) WO1998011918A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7014998B2 (en) 2000-09-30 2006-03-21 Yale University Screening immunomodulatory agents by CTLA-4 upregulation
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds
US20050069538A1 (en) 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
US7265212B2 (en) * 2001-12-03 2007-09-04 Amgen Fremont Inc. Anti-CD45RB antibodies
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20030175270A1 (en) * 2002-01-17 2003-09-18 Josef Penninger Methods of regulating cytokine receptor signaling
CA2491427A1 (en) * 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
US20040146503A1 (en) * 2002-08-28 2004-07-29 Tesi Raymond J. Methods and compositions for inducing stable immune tolerance
US20040047858A1 (en) * 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
EP1658096A1 (en) * 2003-08-25 2006-05-24 PanGenetics B.V. Method of inducing immune tolerance
DE602004026081D1 (de) * 2003-09-18 2010-04-29 Novartis Ag Therapeutische humanisierte antikörper gegen cd45-isoformen
WO2007087453A2 (en) * 2006-01-27 2007-08-02 Cellerant Therapeutics, Inc. Compositions and methods for treating haematological proliferative disorders
US20100034782A1 (en) * 2006-05-31 2010-02-11 Nader Najafian Methods of Using Anti-Thymocyte Globulin and Related Agents
CN104177464B (zh) * 2006-08-18 2017-04-12 阿哥斯医疗公司 Cd83在联合治疗中的用途
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
CN105664147A (zh) 2007-02-07 2016-06-15 日本电气株式会社 用于癌症的治疗剂
WO2013021784A1 (ja) * 2011-08-10 2013-02-14 ナパジェン ファーマ，インコーポレテッド 免疫寛容誘導剤
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP2682462B1 (en) 2011-02-28 2017-11-08 Napajen Pharma, Inc. (nucleic acid)-polysaccharide complex
JP6210879B2 (ja) * 2011-08-10 2017-10-11 ナパジェン ファーマ, インコーポレテッドNapaJen Pharma, Inc. 免疫寛容誘導剤
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US20170226209A1 (en) * 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
EP3858388B1 (en) 2015-09-28 2024-07-03 Regents of the University of Minnesota Chimeric antigen receptor (car) t cells as therapeutic interventions for gvhd
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
CN109641051A (zh) 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
CA3042683A1 (en) 2016-11-07 2018-05-11 Coimmune, Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof
SG11201906319XA (en) 2017-01-20 2019-08-27 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137+ cells
EP3514541A1 (de) 2018-01-17 2019-07-24 Siemens Healthcare Diagnostics Products GmbH Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors
EP3917313A4 (en) * 2019-02-01 2023-02-08 Actinium Pharmaceuticals, Inc. MOLECULES AND THEIR DERIVATIVES AGAINST CD45
CN111707833A (zh) * 2020-06-19 2020-09-25 徐州医科大学 小鼠血管内外淋巴细胞识别的方法及其应用
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス，インコーポレイテッド プロテアーゼ活性化ｃｄ４５ゲートｃａｒ
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
EP4310188A1 (en) 2021-03-17 2024-01-24 Daiichi Sankyo Company, Limited Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
TW202346359A (zh) 2022-04-15 2023-12-01 美商凱維那醫療公司 用於治療自體免疫疾病之方法及組合物
US20240261405A1 (en) 2022-06-08 2024-08-08 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease
CN120554513B (zh) * 2025-07-28 2025-11-21 杭州华大生命科学研究院 一种抗cd45抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626507A (en) * 1980-09-25 1986-12-02 The Salk Institute For Biological Studies Hybridomas producing monoclonal antibodies specific for a human cell surface glycoprotein
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
CA2069342A1 (en) * 1989-10-20 1991-04-21 Herman Waldmann Materials and methods for the treatment of foreign tissue
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
GB9323542D0 (en) * 1993-11-15 1994-01-05 Univ Alberta Lymphocyte marker specific for corhn's disease
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US6174710B1 (en) 1994-08-09 2001-01-16 Pfizer Inc. Spirolaxine derivatives for treating gastrobuodenal diseases

Also Published As

Publication number Publication date
WO1998011918A1 (en) 1998-03-26
CA2266684A1 (en) 1998-03-26
US6379668B1 (en) 2002-04-30
US7160987B2 (en) 2007-01-09
EP0939652A1 (en) 1999-09-08
ATE301471T1 (de) 2005-08-15
ES2247638T3 (es) 2006-03-01
US20020168362A1 (en) 2002-11-14
JP2001501607A (ja) 2001-02-06
DE69733960D1 (de) 2005-09-15
EP0939652B1 (en) 2005-08-10
US6106834A (en) 2000-08-22

Similar Documents

Publication Publication Date Title
US6106834A (en) Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
DE69637131T2 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
DE69637408T2 (de) Antikörper gegen cd-80
DE69032484T4 (de) Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
AU711605B2 (en) CD45RB binding compounds for the prevention of transplant rejection
DE60035057T2 (de) CD40 Antagonist zur Behandlung von Psoriasis
DE60217839T2 (de) Mittel zur suppression von transplantat-abstossung
DE69433820T2 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
JPH10501815A (ja) 抗原特異的ｔ細胞応答の阻害方法
PL170321B1 (pl) Sposób wytwarzania nowej czasteczki wiazacej CD25 PL PL PL PL PL PL
DE69835965T2 (de) CD154-BLOCKADETHERAPIE DER PANKREASINSELZELLTRANSPLANTATION bei Primaten
EP1003552B1 (en) LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION
JP2002500648A (ja) 反適応性の免疫応答、特に移植片拒絶を防ぐためのｃｄ４０：ｃｄ１５４結合妨害剤の使用
AU748533B2 (en) Composition and method to prevent graft rejection and other counter-adaptive T lymphocyte mediated immune responses
DE69825473T2 (de) Cd154-blockadetherapie für das syndrom der hemmung der therapeutischen proteine
EP1600164A2 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
US5830473A (en) Antibodies against T cells as therapeutics
EP0340604B1 (de) Monoklonaler Antikörper und seine Verwendung
AU5725890A (en) Monoclonal antibodies for inducing tolerance
DE69428272T2 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
WO1995013093A1 (en) Treatment of a patient prior to transplantation
DE69737888T2 (de) Anti-mhc klasse ii bindungsreagentien zur verwendung bei xenotransplantationen
Dehoux et al. EFFECTS ON HUMAN AND NONHUMAN PRIMATE IMMUNE RESPONSE OF A NEW RAT ANTI-CD2 MONOCLONAL ANTIBODY1
US7592006B1 (en) Composition comprising the LO-CD2a antibody
DE69928407T2 (de) Ex vivo behandlung von allogenen und xenogenen t-zellen mit gp39-antagonisten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ALIMMUNE L.L.C., TUCSON, ARIZ., US

8339 Ceased/non-payment of the annual fee